"线下展会是我们获客的重要形式，除了9月的法国展会，接下来还有10月的澳大利亚展会、11月的东京 展会等。"黄芳说，公司每年至少参加5场国内外展会，明年可能会增加到7场。 同时，泉州鹏泰服饰有限公司副总经理赵文宏刚结束一场与客户的会议，并将于第二天赶赴公司在柬埔 寨的工厂。"我们是一家集纺织、服装生产、海外销售等为一体的全产业链公司，在石狮市、晋江市、 柬埔寨拥有三大生产基地。"赵文宏告诉记者。 正在法国参加展会的济达（上海）纺织品有限公司创始人、总经理黄芳，在接待客户间隙接受了证券时 报记者采访。 一个在欧洲展会抢订单，一个到东南亚工厂盯生产，黄芳和赵文宏是中国千千万万忙碌的外贸人的缩 影，也是中国外贸在复杂的外部形势下依旧保持韧性的鲜活注脚。海关总署最新数据显示，今年前8个 月，我国货物贸易进出口总值为29.57万亿元，同比增长3.5%。不过，韧性增长的背后亦存在压力与挑 战，关税政策的不确定性、订单碎片化趋势、市场竞争的持续加剧，均考验着变局中的每一个外贸人。 数据印证了市场多元化策略的成效。今年前8个月，我国虽然对美国进出口同比下降13.5%，但对东盟 进出口同比增长9.7%，对欧盟的进出口也同比增长 ...

Core Viewpoint - Despite the challenges posed by global economic recovery and trade protectionism, China's foreign trade has shown resilience, with a year-on-year growth of 3.5% in the first eight months of the year, reaching a total trade value of 29.57 trillion yuan [3][4]. Group 1: Resilience in Foreign Trade - The export value in August was 2.3 trillion yuan, marking a 4.8% year-on-year increase, with six consecutive months of growth [3][4]. - The decline in exports to the U.S. was significant, with a 25% drop in the first half of the year, yet overall exports still grew by 32% [3][4]. - Factors contributing to this resilience include the upgrading of industrial chains and product structures, a diversified market strategy, and supportive policies such as export credit insurance and tax rebates [3][4]. Group 2: Industry Adaptation Strategies - Companies are diversifying their production bases, with some establishing factories in countries like Bangladesh and Cambodia to mitigate tariff impacts [4]. - The market diversification strategy is being emphasized, as evidenced by increased exports to ASEAN and EU markets, which grew by 9.7% and 4.3% respectively in the first eight months [4]. - The shift towards smaller, faster orders has prompted companies to adopt smart manufacturing and digital transformation to enhance flexibility and efficiency [8]. Group 3: Challenges Ahead - Uncertainty in tariff policies, increasing order fragmentation, and intensified market competition are significant challenges facing the foreign trade sector [6][7]. - The export to the U.S. saw a 33.1% year-on-year decline in August, highlighting the impact of tariff uncertainties on business expectations [6][7]. - The shift to smaller orders has led to increased production costs and inefficiencies, particularly for companies that have not yet undergone technological upgrades [8]. Group 4: Future Directions - To address these challenges, a collaborative approach between policy and enterprises is essential, focusing on market and product diversification [10]. - Companies are encouraged to innovate trade models and enhance product value, particularly in high-value sectors like new energy and smart manufacturing [11]. - The emphasis on sustainable products is growing, with companies like Jida (Shanghai) Textile Co. planning to develop eco-friendly clothing to meet consumer demand for sustainability [11].

证券时报记者周春媚张淑贤 正在法国参加展会的济达（上海）纺织品有限公司创始人、总经理黄芳，在接待客户间隙接受了证券时 报记者采访。"线下展会是我们获客的重要形式，除了9月的法国展会，接下来还有10月的澳大利亚展 会、11月的东京展会等。"黄芳说，公司每年至少参加5场国内外展会，明年可能会增加到7场。 同时，泉州鹏泰服饰有限公司副总经理赵文宏刚结束一场与客户的会议，并将于第二天赶赴公司在柬埔 寨的工厂。"我们是一家集纺织、服装生产、海外销售等为一体的全产业链公司，在石狮市、晋江市、 柬埔寨拥有三大生产基地。"赵文宏告诉记者。 一个在欧洲展会抢订单，一个到东南亚工厂盯生产，黄芳和赵文宏是中国千千万万忙碌的外贸人的缩 影，也是中国外贸在复杂的外部形势下依旧保持韧性的鲜活注脚。海关总署最新数据显示，今年前8个 月，我国货物贸易进出口总值为29.57万亿元，同比增长3.5%。不过，韧性增长的背后亦存在压力与挑 战，关税政策的不确定性、订单碎片化趋势、市场竞争的持续加剧，均考验着变局中的每一个外贸人。 保持韧性 今年以来，全球经济复苏乏力，贸易保护主义升温，美国关税政策频繁调整，给全球经贸带来巨大挑 战。但在严峻复杂的外 ...

证券代码：300143 证券简称：盈康生命 投资者关系活动记录表 编号：2025-07 投资者关 系活动类 别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 （电话会议） 参与单位 名称及人 员姓名 南方基金 冯啸 秦乾一 张德曦 陈哲、东证资管 邹秉昂、华创自营 胡建东、易米基金 刘家曦、中泰证券 祝嘉琦 孙宇瑶 余燕伶、平 安证券 裴晓鹏、光大证券 吴佳青、中信证券 沈睦钧 王凯 时间 2025 年 9 月 11 日 地点 山东省青岛市崂山区海尔路 1 号盈康一生大厦 18 楼盈康生命科 技股份有限公司会议室 上市公司 接待人员 姓名 董事会秘书 刘泽霖 投资者关系总监 董丁梦 投资者关 系活动主 要内容介 绍 1、公司在 AI 医疗方面有比较长时间和广泛的布局，请具体介 绍下，以及从经营数据上看有哪些提升效果？ 回答：公司AI应用经历了1.0 阶段（统一整合旗下医院四大核 心系统，实现一体化整合，解决信息孤岛等问题）、2.0 阶段（建 设互联网医院平台，构建"线上+ 线下"一体化服务链，建设大数 据湖，搭建医院管理自日清平台）和AI 应用3.0 阶 ...

（编辑 王雪儿） 证券日报网讯 盈康生命8月26日发布公告，在公司回答调研者提问时表示，公司目前重要子公司主要为 圣诺医疗和优尼器械，圣诺医疗2025年上半年实现收入9723.16万元，同比提升11.21%，实现净利润 1670.68万元，同比提升28.70%。其主要产品在激烈的市场竞争中稳住市场份额，上半年公司输注泵国 内市占率超10%，排名提升至第3位；乳腺钼靶设备国内市占率约10%，排名第3位；高压输注设备及耗 材出货量持续引领。优尼器械上半年实现收入5076.65万元，同比提升12.59%，实现净利润1558.47万 元，同比提升37.75%。圣诺和优尼的渠道协同下，公司进一步突破三甲医院高端市场720多家，三甲医 院覆盖率已超40%。 ...

Core Viewpoint - The company reported a steady growth in net profit for 1H25, driven by advancements in its medical services and medical devices segments, alongside effective cost reduction measures. The outlook for the full year remains positive with an expected net profit growth of 15% [1]. Group 1: Financial Performance - In 1H25, the company achieved revenue of 843 million yuan (+2.4% year-on-year) and a net profit attributable to shareholders of 62 million yuan (+12.8% year-on-year) [1]. - The second quarter saw a quarter-on-quarter increase in revenue and net profit of 6.08% and 6.14%, respectively [1]. - The gross profit margin improved by 0.5 percentage points year-on-year, while the expense ratio decreased by 2 percentage points [1]. Group 2: Medical Services Segment - The medical services segment generated revenue of 653 million yuan in 1H25 (+2.3% year-on-year), with a stable gross margin of 21.24% [2]. - The segment's growth was supported by a 25% year-on-year increase in tumor-related revenue [2]. - The integration of Changsha Kexin Hospital is expected to boost revenue in 2H25, with a profit target of no less than 57 million yuan for the year [2]. Group 3: Medical Devices Segment - The medical devices segment reported revenue of 190 million yuan in 1H25 (+2.8% year-on-year) with a slight increase in gross margin to 46.03% [3]. - The domestic market share for key products has been stable, with over 10% market share in infusion pumps and mammography equipment [3]. - The overseas business experienced a significant growth of 35% year-on-year, driven by a tailored strategy for different markets [3]. Group 4: Profit Forecast and Valuation - The company projects EPS for 2025-2027 to be 0.18, 0.21, and 0.23 yuan, reflecting a downward revision from previous estimates [4]. - A price-to-earnings ratio of 69 times is assigned for 2025, with a target price of 12.42 yuan, up from 11.97 yuan, due to positive expectations for the integration of Changsha Kexin [4].

Financial Performance - The company achieved revenue of 843 million CNY in the first half of 2025, a year-on-year increase of 2.40% [3] - Net profit attributable to shareholders reached 61.83 million CNY, up 12.82% year-on-year [3] - Medical services segment revenue was 653 million CNY, growing 2.28% year-on-year [3] - Medical device segment revenue was 190 million CNY, with a year-on-year increase of 2.80% [3] Oncology Services - Revenue from oncology services reached 215 million CNY, a significant increase of 25.14% [3] - The number of level IV surgeries increased by 6.62% [3] - The outpatient volume at Friendship Hospital reached 24,200 visits, up 21.59% year-on-year [3] - The proportion of level IV surgeries at Friendship Hospital increased by 8 percentage points [3] Medical Device Market - The company’s infusion pump market share exceeded 10%, ranking third in the domestic market [16] - The mammography device market share is approximately 10%, also ranking third [17] - Overseas revenue for medical devices grew by 35% year-on-year [18] AI Integration - AI applications have improved clinical capabilities, reducing complication rates by 10% and average hospital stays by 1-2 days [15] - The efficiency of image diagnosis increased by 66%, and patient follow-up efficiency improved by 300% [15] - Patient Net Promoter Score (NPS) reached 92.5%, surpassing the industry average of 90% [15] Hospital Operations - Sichuan Friendship Hospital generated revenue of 291 million CNY, maintaining stability amid competition [6] - Suzhou Guangci Hospital achieved revenue of 269 million CNY, with a year-on-year growth of 1.69% [7] - The company’s managed hospitals, including Yuncheng Hospital, have seen significant operational improvements, with surgical volumes increasing by 18% [12] Strategic Developments - The acquisition of Changsha Kexin Oncology Hospital enhances the company’s oncology ecosystem and regional presence [10] - The company is focusing on differentiated services and expanding its service ecosystem through partnerships and AI integration [9]

中证报中证网讯(王珞)8月24日晚间，盈康生命（300143）发布半年度报告，数据显示，公司上半年实 现营业收入8.43亿元，同比增长2.4%；归属于上市公司股东的净利润6182.72万元，同比增长12.8%；扣 非归母净利润6058.99万元，同比增长19.2%，实现营收与净利润双增长。毛利率同比提升0.5个百分 点，费用率同比下降2个百分点，经营提质增效明显，公司实现持续高质量发展。 诊疗能力升级，驱动肿瘤规模及行业影响力提升。报告显示，公司肿瘤收入2.15亿元，同比增长 25.14%，肿瘤诊疗人次快速增长、肿瘤四级手术量显著增加。报告期内，友谊医院先后获评国家标准 化癌症筛查AAA级管理中心试点单位、CSCO"省市级肿瘤患者营养指导中心优秀单位"，区域口碑与专 业影响力持续强化，肿瘤诊疗能力和资质持续提升。 区域布局拓展至华中，外延式发展战略持续落地。盈康生命上半年收购长沙珂信肿瘤医院并完成交割， 该医院作为三级肿瘤专科医院，以肿瘤微创介入治疗技术为优势特色，头颈部肿瘤治疗能力实现区域引 领，长沙珂信的加入进一步丰富公司肿瘤预诊治康生态，为上市公司发展再添动能。 AI赋能提质增效 当前，盈康生命已实现" ...

Summary of Yingkang Life's Conference Call Company Overview - **Company**: Yingkang Life - **Industry**: Healthcare and Medical Services Key Financial Performance - **Total Revenue**: 8.43 billion yuan in H1 2025, up 2.4% year-on-year [3] - **Net Profit**: 61.83 million yuan, up 12.82% year-on-year [3] - **Medical Services Revenue**: 6.53 billion yuan, up 2.28% year-on-year [2] - **Medical Devices Revenue**: 1.9 billion yuan, up 2.8% year-on-year [6] Medical Services Segment - **Oncology Revenue**: 2.15 billion yuan, up 25.14% year-on-year [2] - **Surgical Volume**: Increased by 6.62% for tertiary and quaternary surgeries [2] - **Outpatient Visits**: 24,200 visits for oncology outpatient services, up 21.59% [4] - **Hospital Performance**: Key indicators improved, with inpatient visits up 17% [9] Medical Devices Segment - **Equipment and Consumables Revenue**: Increased by 13.34% [6] - **Overseas Market Growth**: Revenue up 35%, now accounting for 30% of total revenue [6] Strategic Initiatives - **AI Empowerment**: Business model reconstruction through AI to enhance management and diagnostic capabilities [2][7] - **Comprehensive Treatment System**: Development of a full-cycle treatment service system to optimize disease structure and improve CMI values [8] - **Regional Expansion**: Physical bed capacity expansion to solidify regional medical centers [12] Challenges and Responses - **Industry Changes**: Facing challenges from medical reform, payment method changes, and volume-based procurement [7] - **Operational Efficiency**: Focus on lean operations and personalized services to enhance competitiveness [7][15] - **Policy Adaptation**: Adjusting to DRG 2.0 and optimizing service offerings to maintain revenue [8][16] Future Growth Strategies - **Out-of-Hospital Revenue**: Targeting growth through AI health management services [14] - **Investment and M&A**: Plans for future project investments and acquisitions as appropriate [14] - **Innovative Medical Devices**: Ongoing development of new products for potential inclusion in DRG exclusion payment directory [23] Additional Insights - **User Experience**: Enhancing patient experience through differentiated health management solutions [10] - **Cost Management**: Strengthening drug and consumable management to optimize clinical pathways [9][20] - **Market Positioning**: Maintaining a competitive edge through innovative technologies and personalized care [19][22] This summary encapsulates the key points from Yingkang Life's conference call, highlighting financial performance, strategic initiatives, challenges, and future growth plans.

Core Insights - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, attributed to both external acquisitions and internal growth driven by AI technology [1][2]. Financial Performance - The company achieved a revenue of 843 million yuan, a year-on-year increase of 2.4% [1]. - The net profit attributable to shareholders was 61.83 million yuan, reflecting a year-on-year growth of 12.8% [1]. Business Segments - The medical services segment generated 653 million yuan in revenue, with the oncology business being a key growth driver, contributing 215 million yuan, a 25.14% increase year-on-year [2]. - The company completed the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, enhancing its presence in the central China region [2]. Operational Efficiency - The overall expense ratio decreased by 2 percentage points, while the average service volume per employee increased by 10% [3]. - The company reported an average revenue per employee of 710,000 yuan, up 8.9%, and an average profit per employee of 52,600 yuan, up 20.2% [3]. Market Expansion - The overseas market revenue grew by 35% year-on-year, while the domestic market share also showed steady improvement [3]. - The company achieved significant milestones in product registration and certification, including the EU MDR certification for its third-generation digital mammography machine [3]. Strategic Focus - The company aims to diversify its product offerings across tumor prevention, diagnosis, treatment, and health management to reduce reliance on overseas markets [5].